Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
16 October 2019

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 399.70
Net Changes 2.90
Volume 5503380
Prev Close 396.80
399.70 2.90 (0.73%)
Date: Oct 16,2019 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 399 Div Yield (%) 0.69
Buy (Size) 398.20(×500) Eps(Rs) 9.13
Sell (Size) 399.15(×367) Book Value (Stand.)(Rs) 95.21
Value 7608627600 Book Value(conso.)(Rs) 172.59
Buy Quantity 500 Market Cap(Rs.Cr) 95853.43
Sell Quantity 367 Face Value(Rs) 1
Today's High 402 Market Lot 1
Today's Low 394.7 AGM Date Aug
52-Week High 616.5 Book Closure Date Aug
52-Week Low 350.4 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1304855381 54.38
Total of Promoter 1304855381 54.38
Non Promoter (Institution) 789571100 32.91
Non Promoter (Non-Institution) 304908489 12.71
Total Non Promoter 1094479589 45.62
Total Promoter & Non Promoter 2399334970 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 2399334970 100.00

Company News

16-Oct-2019  Sun Pharma launches Drizalma Sprinkle™ in U.S. market
Sun Pharma launches Drizalma Sprinkle™ in U.S. market

Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle™ (duloxetine delayed-release capsules) in the U.S. for oral use. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a problem that is estimated to affect approximately 30-35% of long-term care residents. The U.S. Food and Drug Administration (FDA) approved Drizalma Sprinkle on 19 July 2019.
14-Oct-2019  Sun Pharma launches CEQUA 0.09% in US
Sun Pharma launches CEQUA 0.09% in US

Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the U.S.1 CEQUA is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL™) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.
14-Oct-2019  Sun Pharma gains on launching cyclosporine ophthalmic solution...
Sun Pharma gains on launching cyclosporine ophthalmic solution in US

Sun Pharmaceutical Industries announced before market hours today, 14 October 2019, that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the United States.

CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (USFDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the U.S.

CEQUA is the first and only USFDA-approved cyclosporine treatment delivered with nanomicellar (NCELL) technology, which helps to improve the bio availability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

Recently, Sun Pharma's Netherlands subsidiary had concluded its acquisition of PJSC Biosintez, Russia. The acquired entity is mainly engaged in the manufacture and marketing of pharmaceutical products used in hospital segment of the market, with presence in Russia and CIS countries.

Meanwhile, the S&P BSE Sensex was up 226 points or 0.59% to 38352.91.

On the BSE, 86,235 shares were traded in the Sun Pharma counter so far compared with average daily volumes of 2.44 lakh shares in the past two weeks. The stock hit a high of Rs 396.6 and a low of Rs 386.3 so far during the day.

The stock hit a 52-week high of Rs 616.5 on 22 Oct 2018. The stock hit a 52-week low of Rs 350.4 on 13 May 2019.

On a consolidated basis, the pharmaceutical company's net profit rose 31.2% to Rs 1,387.48 crore on a 15.7% rise in the net sales to Rs 8,259.30 crore in Q1 June 2019 over Q1 June 2018.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

14-Oct-2019  Sun Pharmaceuticals Industries Ltd - Announcement under Regula...
Sun Pharmaceuticals Industries Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Please find enclosed herewith our Press Release relating to launch of CEQUA for the treatment of dry eye disease in the US, which we shall be releasing after sending this letter to you. This is for your information and record.
14-Oct-2019  Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31...
Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 14, 2019 for Raksha Sudhir Valia
14-Oct-2019  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Press Release

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 14, 2019, titled 'Launch of CEQUA for the Treatment of Dry Eye Disease in the US'.
12-Oct-2019  Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31...
Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2019 for Shanghvi Finance Pvt Ltd
12-Oct-2019  Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) -...
Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Please find enclosed, intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
10-Oct-2019  Sun Pharmaceuticals Industries Ltd - Compliance Certificate -...
Sun Pharmaceuticals Industries Ltd - Compliance Certificate - Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Please find enclosed Compliance Certificate under Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
10-Oct-2019  Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) -...
Sun Pharmaceuticals Industries Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Please find enclosed details of loss of share certificates
Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
Vadodara,
Gujarat-390020
Telephone 91-265-6615500 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor S R B C & Co LLP 
Face Value(Rs)
Market Lot
Listing MSEI,BSE,NSE 
Registrar Link Intime India Pvt Ltd
C-101 247 Park,L B S Marg,Vikhroli West,Mumbai-400083 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS